Efficacy of Rheocarna®, a Novel Apheresis Device, in Patients With No- or Poor-Option Chronic Limb-Threatening Ischemia
Circulation Journal · 25.04.2025 · 89 (5) · 557-565
DOI: 10.1253/circj.cj-24-0830 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Circulation Journal, erschienen am 25.04.2025. Verfasst von Yoshimitsu Soga und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Kokura Memorial Hospital. Hauptthemen laut MEDLINE: Blood Component Removal, Chronic Limb-Threatening Ischemia, Ischemia, Peripheral Arterial Disease. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Although revascularization is first-line therapy for chronic limb-threatening ischemia (CLTI), there are no established treatments for patients in whom revascularization is not (or is a poor) option, including CLTI that has responded poorly to revascularization. This study verified the efficacy of the Rheocarna®, a novel apheresis device, for no-option CLTI or poor-response CLTI after revascularization. METHODS AND RESULTS: This multicenter retrospective observational study analyzed 221 patients (221 limbs) with no- or poor-option CLTI (mean [±SD] age 71±10 years; males, 70.1%; diabetes, 76.5%; dialysis, 87.8%; Rutherford category 6, 26.4%) undergoing apheresis with the Rheocarna between March 2021 and March 2022. The primary endpoint was the 1-year wound-healing rate. After apheresis with the Rheocarna, C-reactive protein, fibrinogen, and low-density lipoprotein cholesterol (LDL-C) levels decreased significantly, and the ankle-brachial index (ABI) and skin perfusion pressure (SPP) increased significantly (all P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Kokura Memorial Hospital.
- Department of Diabetes Care Medicine, Osaka University Graduate School of Medicine.
- Cardiovascular Center, Takatsu General Hospital.
- Cardiovascular Division, Osaka International Medicine and Science Center.
- Department of Cardiology, Kishiwada Tokushukai Hospital.
- Department of Cardiology, Morinomiya Hospital.
Zitieren
APA
Soga, Y., Takahara, M., Yamauchi, Y., Iida, O., Fujihara, M., Kawasaki, D., Horie, K., Kozuki, A., Takei, T., & TURNIP Investigators (2025). Efficacy of Rheocarna®, a Novel Apheresis Device, in Patients With No- or Poor-Option Chronic Limb-Threatening Ischemia. Circulation Journal, 89(5), 557-565. https://doi.org/10.1253/circj.cj-24-0830
Vancouver
Soga Y, Takahara M, Yamauchi Y, Iida O, Fujihara M, Kawasaki D, et al. Efficacy of Rheocarna®, a Novel Apheresis Device, in Patients With No- or Poor-Option Chronic Limb-Threatening Ischemia. Circulation Journal. 2025;89(5):557-565. doi:10.1253/circj.cj-24-0830
BibTeX
@article{Soga2025,
author = {Soga, Yoshimitsu and Takahara, Mitsuyoshi and Yamauchi, Yasutaka and Iida, Osamu and Fujihara, Masahiko and Kawasaki, Daizo and Horie, Kazunori and Kozuki, Amane and Takei, Tatsuro and TURNIP Investigators, TURNIP Investigators},
title = {Efficacy of Rheocarna®, a Novel Apheresis Device, in Patients With No- or Poor-Option Chronic Limb-Threatening Ischemia},
journal = {Circulation Journal},
year = {2025},
volume = {89},
number = {5},
pages = {557--565},
doi = {10.1253/circj.cj-24-0830}
}
EUVIMED